NasdaqCM - Delayed Quote • USD
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
At close: 4:00 PM EDT
After hours: 5:54 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -1.38 | -1.51 | -5.33 | -4.98 |
| Low Estimate | -1.71 | -2.06 | -6.99 | -6.47 |
| High Estimate | -1.1 | -1.11 | -4.26 | -3.33 |
| Year Ago EPS | -2.05 | -2.05 | -10.31 | -5.33 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | 3.33M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 10M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -3.1 | -2.06 | -2.36 | -1.09 |
| EPS Actual | -2.05 | -2.05 | -1.81 | -0.83 |
| Difference | 1.05 | 0.01 | 0.55 | 0.26 |
| Surprise % | 33.90% | 0.50% | 23.30% | 23.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.38 | -1.51 | -5.33 | -4.98 |
| 7 Days Ago | -1.38 | -1.51 | -5.33 | -4.98 |
| 30 Days Ago | -1.2 | -1.37 | -5.2 | -5.12 |
| 60 Days Ago | -1.2 | -1.37 | -5.2 | -5.12 |
| 90 Days Ago | -1.67 | -1.94 | -7.26 | -7.02 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CRBP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 32.70% | -- | -- | 8.90% |
| Next Qtr. | 26.30% | -- | -- | 11.40% |
| Current Year | 48.30% | -- | -- | 5.70% |
| Next Year | 6.60% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.43% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Oppenheimer: Outperform to Outperform | 6/3/2024 |
| Initiated | RBC Capital: Outperform | 5/13/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 5/8/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 3/13/2024 |
| Upgrade | Jefferies: Hold to Buy | 3/6/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 1/29/2024 |
Related Tickers
JANX Janux Therapeutics, Inc.
42.59
-8.94%
IMVT Immunovant, Inc.
25.43
-0.66%
IMCR Immunocore Holdings plc
42.69
-0.84%
TERN Terns Pharmaceuticals, Inc.
7.28
+5.97%
MRUS Merus N.V.
53.71
+2.50%
AGIO Agios Pharmaceuticals, Inc.
47.80
-2.11%
CYTK Cytokinetics, Incorporated
52.28
-4.21%
ELEV Elevation Oncology, Inc.
3.6800
-1.08%
BBIO BridgeBio Pharma, Inc.
27.12
-3.14%
CADL Candel Therapeutics, Inc.
7.12
-11.33%